ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag trial participants microbiology disease medicine

Haydeh Payami is wearing a purple dress and an orange and pink scarf and standing in front of a whiteboard.
A Microbial Link to Parkinson’s Disease
Mariella Bodemeier Loayza Careaga, PhD | Dec 4, 2023 | 6 min read
Haydeh Payami helped uncover the genetic basis of Parkinson’s disease. Now, she hopes to find new ways to treat the disease by studying the gut microbiome.
A surgical mask next to an open pill bottle that’s toppled over, spilling out red capsules meant to represent vitamin D supplements.
Vitamin D Likely Doesn’t Prevent COVID-19, Studies Find
Dan Robitzski | Sep 9, 2022 | 2 min read
The results from two large clinical trials don't support the idea that supplements of the vitamin bolster immune defenses against SARS-CoV-2.
An illustration of a pregnant women wearing a mask, surrounded by microbes
How COVID-19 Affects Pregnancy
Amanda Heidt | Aug 16, 2022 | 10 min read
Evidence thus far shows that pregnant people infected with SARS-CoV-2 are at higher risk for severe disease and death, as well as complications in their pregnancies.
Updated
Merck research facility in San Francisco
Antiviral Pill Lowers Risks of COVID-19 Hospitalization, Death
Chloe Tenn | Oct 1, 2021 | 3 min read
Merck reports that its antiviral molnupiravir was effective against early stages of COVID-19 in high-risk patients in a Phase 3 clinical trial.
Woman in face shield and blue gown taking cotton swab of patient's mouth while patient sits inside of car
What You Should Know About New Omicron Subvariants
Natalia Mesa, PhD | May 17, 2022 | 6 min read
The presence and spread of new, more-infectious and immune-evading variants show that the coronavirus is not done mutating.
A person in a white shirt activates a nasal spray
Oxford-AstraZeneca Nasal COVID-19 Vaccine Falters in Clinical Trial
Dan Robitzski | Oct 11, 2022 | 2 min read
Researchers say they’re abandoning the project in its current form—one of several that aims to induce what’s known as mucosal immunity against SARS-CoV-2.
illustration of green viral particles flowing into a person's nostril
First COVID-19 Human Challenge Trial Reveals Uneven Susceptibility
Shawna Williams | Feb 3, 2022 | 2 min read
Only half of volunteers deliberately exposed to SARS-CoV-2 developed an infection. None developed serious symptoms, paving the way for further challenge trials.
oxford astrazeneza covid-19 vaccine sars-cov-2 coronavirus pandemic clinical trial phase 2 US chile peru hospitalization
AstraZeneca’s COVID-19 Shot Completely Prevented Severe Disease
Kerry Grens | Mar 22, 2021 | 2 min read
The vaccine was 79 percent effective at blocking symptomatic infections, according to data from a Phase 3 trial in the US, Chile, and Peru. A US safety oversight board says the data might be incomplete.
Round white pills on a wooden surface
No Reduction in COVID-19 Hospitalizations, Deaths with Ivermectin
Catherine Offord | Jun 13, 2022 | 2 min read
The ACTIV-6 trial reports that people who took the drug for three days may have spent slightly less time feeling unwell with SARS-CoV-2, but fails to find differences in disease progression between the treatment and placebo groups.
Molecular structure of fluvoxamine
A Closer Look at the New Fluvoxamine Trial Data
Catherine Offord | Nov 2, 2021 | 8 min read
Authors of a newly published study on the use of an antidepressant for COVID-19 claim the drug greatly reduces hospitalizations and mortality. But some experts question whether that’s really what the data show.

Run a Search

ADVERTISEMENT